Differences between EA and non-EA patients were observed for age, Eastern Cooperative Oncology Group performance status (ECOG PS), etiology of liver disease, primary tumor present, presence of extra-hepatic spread, Barcelona Clinic Liver Cancer stage, baseline AFP, prior systemic therapy, and reasons for discontinuation of prior sorafenib therapy. The gene discussed is AFP; the disease is liver cancer.